Products

Dermalyser
AI Medical Technology
Dermatology AI
Dermalyser is a CE-marked, AI-powered decision support app for medical professionals, offering 96% accuracy in assessing skin lesions from smartphone-captured dermatoscopic images, aiming for faster, safer skin cancer diagnoses.

See all 1 product →

About AI Medical Technology

AI Medical Technology, through its flagship product Dermalyser, offers a CE-marked, AI-driven diagnostic decision support system specifically designed for skin cancer detection, with a primary focus on melanoma. This smartphone application, used in conjunction with a dermatoscope, enables licensed healthcare professionals such as primary care physicians, dermatologists, and general practitioners to capture and analyze dermoscopic images of suspicious skin lesions. The system provides an immediate risk score, aiming to enhance diagnostic precision and speed in clinical settings.

Dermalyser is clinically validated, demonstrating high accuracy with a 96% Area Under the Receiver Operating Characteristic Curve (AUC), 95% sensitivity, and 84.5% specificity for melanoma detection, and notably 100% sensitivity for invasive melanomas. By offering a rapid, accurate “second opinion,” the technology helps minimize false positives, reduce unnecessary referrals and treatments, and optimize clinical workflows, ultimately contributing to improved patient outcomes and reduced healthcare costs. It functions as an intelligent assistant, ensuring that the final diagnostic decision always remains with the physician.

What Physicians Need to Know

Specialization
AI Medical Technology specializes in AI-powered diagnostic decision support for skin lesions, with a primary focus on the early and accurate detection of melanoma. Their flagship product, Dermalyser, assists healthcare professionals in assessing suspected skin cancers.
Key Differentiators
Dermalyser stands out due to its clinically validated AI technique, achieving an Area Under the Receiver Operating Characteristic (AUROC) of 0.960 for melanoma detection, with 95.2% sensitivity and 84.5% specificity. For invasive melanomas, it boasts 100% sensitivity and 92.6% specificity, outperforming expert dermatologists (AUROC 0.85) and general practitioners (AUROC 0.70). It provides immediate analysis within 5 seconds, significantly reducing patient wait times and improving workflow efficiency. The solution is CE-marked as a Class IIa medical device, ensuring regulatory compliance and safety. It also offers a high Negative Predictive Value (NPV) of 99.8%, providing strong confidence in ruling out malignancy.
Technology Stack
The core technology involves advanced artificial intelligence and deep learning for image analysis of dermatoscopic images. Dermalyser operates as a smartphone application, designed to be used with a compatible dermatoscope attached to the mobile phone camera. They also offer DermAIM, an AI engine delivered via secure APIs, for integration into broader healthcare platforms.
Physician Value Proposition
For physicians, Dermalyser acts as an instant decision support tool, offering a highly accurate 'second opinion' for skin lesion evaluations. It enhances diagnostic precision, minimizes false positives, and helps avoid unnecessary treatments and referrals, leading to significant cost savings (up to 56%) and a 79% reduction in referrals. The tool is designed to be intuitive and fast, optimizing clinical workflow and boosting confidence in diagnoses, while always ensuring the diagnostic decision remains with the doctor.
Physician Tip

For physicians considering Dermalyser, leverage its rapid 5-second analysis for immediate diagnostic support during consultations, especially in primary care settings where quick, accurate initial assessments are crucial. Integrate it into your workflow to reduce unnecessary referrals and improve patient flow, trusting its high sensitivity for melanoma detection, particularly for invasive cases. Remember that Dermalyser is a decision-support tool; the final diagnosis and treatment plan always remain your responsibility. Ensure proper training and adherence to usage guidelines, especially regarding the types of lesions and patient age for which it is validated.

AI Medical Technology offers DermAIM, an AI engine accessible via secure APIs, enabling seamless integration of their clinically validated skin lesion risk assessment capabilities into existing healthcare platforms and systems. This allows for broader adoption and incorporation into various clinical workflows and electronic health records.

Products by AI Medical Technology

1 product in the directory

Dermalyser
AI Medical Technology
Dermatology AI
Dermalyser is a CE-marked, AI-powered decision support app for medical professionals, offering 96% accuracy in assessing skin lesions from smartphone-captured dermatoscopic images, aiming for faster, safer skin cancer diagnoses.

What the Web Says

AI Medical Technology, particularly known for its Dermalyser product, receives generally positive feedback for its innovative application of AI in dermatology, improving diagnostic accuracy and efficiency. However, some user experiences highlight a learning curve and potential for integration challenges with existing systems.

Overall: Positive

Strengths

  • Enhances diagnostic accuracy in dermatology using AI.
  • Improves efficiency in clinical workflows.
  • User-friendly interface for medical professionals.
  • Potential for early detection of skin conditions.
  • Strong focus on medical technology innovation.
  • Positive impact on patient care through better diagnostics.

Limitations

  • Steep learning curve for some users.
  • Potential integration challenges with legacy IT systems.
  • Reliance on high-quality image input for optimal performance.
  • Cost of implementation and subscription may be a barrier for smaller practices.
  • Limited information available on employer reviews (Glassdoor).
  • Specific feature requests or improvements mentioned by some users.

Based on reviews from: G2, Capterra, Healthcare IT Reviewers, Reddit

Last updated: 2026-07-30

Videos

News, demos, and interviews about AI Medical Technology.

Loading videos...

Videos load interactively. If none appear, search YouTube for AI Medical Technology →

View all on YouTube

Press & Coverage

Drug and Device World
AI-powered melanoma app Dermalyser scores EU's CE mark
AI Medical Technology's Dermalyser, an AI-powered smartphone application for melanoma detection, has received CE mark approval for use across the European Union. The company plans to expand its footprint in Europe in 2025 and launch in the US in 2027.
2025-05
unknown
Dermalyser Secures CE Mark in Europe for AI-Powered Melanoma Detection Tool
AI Medical Technology announced CE mark certification for Dermalyser, its AI-driven diagnostic decision support tool for melanoma, enabling immediate commercial use in Europe. A US launch is anticipated in 2027, pending FDA 510(k) clearance.
2025-05
Cision News
Dermalyser Receives CE Mark In Europe, Paving Way to Market for World's Best Melanoma Diagnostic Decision Support Tool
AI Medical Technology has received European CE mark approval for Dermalyser, its smartphone-based diagnosis decision support tool for melanoma detection. The company will now commence full commercial operations in Europe.
2025-05
PharmaShots
AI Medical Technology's Dermalyser Receives European CE Mark Approval for Melanoma Detection
AI Medical Technology announced CE mark approval for Dermalyser for melanoma detection, with commercialization starting in 2025. The Dermalyser was validated in the AI-DSMM study, demonstrating high sensitivity and specificity.
2025-05
Canada Newswire
AI Medical Technology: New Swedish clinical study published in the British Journal of Dermatology demonstrates superiority of AI-algorithm guided melanoma diagnosis
A new clinical study published in the British Journal of Dermatology demonstrates the superior diagnostic precision of AI-algorithm guided melanoma diagnosis using AI Medical Technology's Dermalyser. The study, conducted in 37 Swedish primary care facilities, showed that the AI can revolutionize melanoma diagnosis.
2024-03
Karolinska Institutet
AI-based app can help physicians find skin melanoma
A study led by Linku00f6ping University, published in the British Journal of Dermatology, shows that the Dermalyser mobile app, which uses AI to analyze images of suspected skin lesions, can diagnose melanoma with very high precision in primary care.
2024-03
Health Tech Digital
Skin cancer diagnostic company AI Medical Technology raises SEK12m (US$1m) via an oversubscribed bridge financing round in anticipation of a significant Series A later this year
AI Medical Technology successfully closed an oversubscribed bridge financing round, raising SEK12 million (US$1 million) from existing and new investors. The funds will support regulatory efforts and the development of Dermalyser, with a Series A round planned for later this year and an IPO in 2027-2028.
2024-05
ArcticStartup
Swedish medtech nets u20ac961K to accelerate Dermalyser AI-driven diagnostic support tool for skin cancer
AI Medical Technology completed an oversubscribed fundraising round, raising u20ac961K (SEK10.8 million) to expand clinical trials for Dermalyser in Europe, obtain CE marking, and commercialize the product. The company is also working towards FDA approval for the US market.
2023-01

Frequently Asked Questions

AI Medical Technology primarily offers Dermalyser, an AI-driven tool designed to support clinicians in diagnosing skin cancer. This solution provides instant analysis of dermatoscopic images captured with a smartphone, acting as a 'second set of eyes' to aid in accurate decision-making.
AI Medical Technology's Dermalyser is CE-marked, indicating compliance as a medical device under EU MDR 2017/745. The company also adheres to stringent data handling practices, secure infrastructure, and typically requires Business Associate Agreements to ensure HIPAA compliance and protect Protected Health Information (PHI).
While specific pricing for Dermalyser is not publicly detailed, healthcare AI pricing models often include per-study or per-image fees, fixed costs for well-defined projects, or consumption-based models for variable demand. These structures aim to align with hospital budgets and account for regulatory and liability factors.
Healthcare AI solutions typically aim for seamless integration with existing IT stacks, including PACS, VNA, worklists, and EHR systems to ensure smooth clinical adoption. Support often includes ongoing maintenance, model updates, and technical assistance to ensure continuous, efficient operation and compliance.
Dermalyser has been clinically validated and boasts a 96% accuracy (AUC) in assessing skin lesions, providing reliable decision support for clinicians. This validation helps doctors make more accurate diagnoses and potentially reduce unnecessary procedures.
AI Medical Technology was founded by physicians, scientists, and innovators with the core purpose of empowering healthcare professionals to provide the best possible patient diagnoses. The company is headquartered in Stockholm, Sweden, and focuses on leveraging AI to strengthen medical expertise and improve daily practice efficiency and safety.
The company was founded by a team of doctors, physicians, scientists, and innovators, indicating a collaborative origin. In the broader healthcare AI landscape, partnerships are crucial for technology transfer, data sharing, and integrating AI solutions into diverse healthcare systems.

Related Companies

Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]

TalkToMedi is a Canadian healthcare AI company that has developed a clinical-grade voice AI platform called MEDI. This platform is designed to automate patient communication and administrative tasks for medical clinics, including family medicine, specialty clinics, allied health, and physiotherapy. MEDI handles high-volume patient calls, automating appointment inquiries, booking, rescheduling, and cancellations based on the […]

Menaela is an AI-first practice management system designed for solo practitioners, small private clinics, and clinic owners. It integrates patient communication, scheduling, CRM, and medical documentation into a single platform, aiming to replace multiple disconnected tools and bots. The system features an AI practice manager that understands natural-language requests, utilizes real clinic data, and performs […]

Avie (avie.me) is a healthcare AI company that focuses on providing a next-generation, whole-person health approach, bridging the gap between clinical and holistic care. The company connects individuals with providers and clinicians who can support their unique physical, emotional, cognitive, and logistical needs. Avie emphasizes fusing physical and mental best practices to enhance overall health, […]

Saile is a physician-founded healthcare technology company that addresses critical inefficiencies in healthcare staffing and credentialing. Their AI-powered platform acts as a “universal credential passport” for physicians, centralizing and managing all medical licenses, certifications, and CME credits in one secure, portable vault. This system aims to significantly reduce the administrative burden and delays associated with […]

Data Capture Experts (DCE) is an Australian-based healthcare AI company that is at the forefront of digital health transformation. They specialize in developing and implementing digital health platforms that integrate data, technology, and human-centered design to create intuitive and connected healthcare systems. Their flagship platform, DC2Vue, is designed to go beyond traditional Electronic Medical Records […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.